A Class in Session: Understanding Current and Future Therapeutic Advances Across B-Cell Lymphomas

Join us for this live symposium featuring presentations and panel discussions with perspectives and recommendations from experts on the rapidly changing clinical data for managing patients with B-cell lymphomas, including new advances in indolent NHL and aggressive B-cell lymphomas, as well as information on treatment of Epstein-Barr virus (EBV)–associated PTLD.

You will have multiple opportunities to interact with faculty through questions on patient case scenarios and audience Q&A sessions.

Friday Satellite Symposium on A Class in Session: Understanding Current and Future Therapeutic Advances Across B-Cell Lymphomas, preceding the 63rd ASH Annual Meeting and Exposition.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.



Welcome and Introduction

New Advances in Indolent NHL
Patient selection and sequencing of new and emerging agents within the patient care continuum

  • Patient case examples: Follicular Lymphoma
  • Patient case examples: MZL

New Advances in Aggressive B-Cell Lymphomas
Patient selection and sequencing of new and emerging agents within the patient care continuum

  • Patient case example: MCL
  • Patient case example: DLBCL

Novel Approaches to the Treatment of EBV-Associated Posttransplant Lymphoproliferative Disease

  • Clinical outcomes from current approaches with chemoimmunotherapy
  • Promising new and emerging therapies

Panel Discussion: Addressing Key Challenges and Future Directions

Final Thoughts


Date / Time
Event Details


Program Director
Julie M. Vose, MD, MBA

Chief, Division of Oncology and Hematology
Neumann M. and Mildred E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Brad S. Kahl, MD

Professor of Medicine
Department of Medical Oncology
Washington University School of Medicine
St Louis, Missouri

John P. Leonard, MD

Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Professor of Medicine
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of physicians and other healthcare providers to optimally integrate evolving data in B-cell lymphomas into practice to optimize patient care.

Target Audience
This program is intended for physicians and other healthcare professionals who care for patients with B-cell lymphomas.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Order and interpret molecular profiling for appropriate patients with B-cell lymphoma to guide therapy selection
  • Select treatment regimens for patients with B-cell lymphoma based on available clinical data, disease characteristics, and individual patient goals and preferences to optimize clinical outcomes
  • Identify patients with B-cell lymphoma who would likely benefit from enrollment on a clinical trial
  • Mitigate, monitor, and manage adverse events associated with newer therapeutic regimens used in the treatment of indolent and aggressive B-cell lymphomas


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.